Clinical Trial Update: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] [Phase 3]

View source ↗

Summary

Phase 3 study comparing ABP 938 to Aflibercept (Eylea) in neovascular (wet) age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• ABP 938 (aflibercept biosimilar)
• Aflibercept (Aflibercept)

Snippet

Sponsor: Amgen | Conditions: Neovascular (Wet) Age-related Macular Degeneration (AMD) | Phase 3 | Status: COMPLETED | Results posted: 2024-01-05